Traditional Chinese medicines treat ischemic stroke and their main bioactive constituents and mechanisms

Abstract

Ischemic stroke (IS) remains one of the leading causes of death and disability in humans. Unfortunately, none of the treatments effectively provide functional benefits to patients with IS, although many do so by targeting different aspects of the ischemic cascade response. The advantages of traditional Chinese medicine (TCM) in preventing and treating IS are obvious in terms of early treatment and global coordination. The efficacy of TCM and its bioactive constituents has been scientifically proven over the past decades. Based on clinical trials, this article provides a review of commonly used TCM patent medicines and herbal decoctions indicated for IS. In addition, this paper also reviews the mechanisms of bioactive constituents in TCM for the treatment of IS in recent years, both domestically and internationally. A comprehensive review of preclinical and clinical studies will hopefully provide new ideas to address the threat of IS.

In Vitro Metabolism and In Vivo Pharmacokinetics Profiles of Hydroxy-α-Sanshool

“…Currently, accumulating lends support to the view that traditional Chinese medicines (TCMs) and their monomers are important resources for finding various candidate drugs [ 13 , 14 ]. Pharmacokinetic studies of TCMs are of great significance in revealing the active substances and mechanisms of TCMs, designing and optimizing the route of administration of TCM, promoting the new drugs development, improving the dosage form, and controlling the quality of TCM [ 15 ].…”